Randomized, double-blind, phase III. Pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in healthy infants and children in Peru

American Journal of Tropical Medicine and Hygiene

Volumn 72, Issue 2, 2005, Pages 189-197

  Belmusto Worn, Vivian E ^a,b   Sanchez, Jose L ^c   McCarthy, Karen ^d   Nichols, Richard ^d   Bautista, Christian T ^a,b   Magill, Alan J ^c   Pastor Cauna, Giovanna ^e   Echevarria, Carlos ^e   Laguna Torres, Victor A ^a,b   Samame, Billey K ^f   Baldeon, Maria E ^g   Burans, James P ^h   Olson, James G ^a   Bedford, Philip ^d   Kitchener, Scott ⁱ   Monath, Thomas P ^d  

^a California   (Peru)

^b Embassy of Belgium in Lima   (Peru)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d Acambis   (United States)

^e PRA International   (Peru)

^f US Naval Medical Research Center Detachment ^*

^g MINISTERIO DE SALUD   (Peru)

^h U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

YELLOW FEVER VACCINE; VIRUS ANTIBODY;

ANALYSIS OF VARIANCE; ANTIBODY TITER; APPETITE DISORDER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; MALAISE; NORMAL HUMAN; PERU; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; VOMITING; YELLOW FEVER; BLOOD; FEMALE; IMMUNOLOGY; MALE; PRESCHOOL CHILD; SERODIAGNOSIS; TREATMENT OUTCOME; VACCINATION; YELLOW FEVER FLAVIVIRUS;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEUTRALIZATION TESTS; PERU; TREATMENT OUTCOME; VACCINATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 15844430485     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.72.189     Document Type: Article

References (28)

1. Monath TP. 2003. Yellow fever. Plotkin SA, Orenstein WA, eds. Vaccines. Fourth edition. Philadelphia: W. B. Saunders. 1095-1176.
2. Monath TP. 2001. Yellow fever: an update. Lancet Infect Dis 1: 11-20.
3. Robertson SE, Hull BP, Tomori O, Bele O, Leduc JW, Esteves K. 1996. Yellow fever: a decade of reemergence. JAMA 276: 1157-1162.
4. Monath TP, Cetron M. 2002. Prevention of yellow fever in persons traveling to the tropics. Clin Inject Dis 34: 1369-1378.
5. Theiler M. 1951. The virus. Strode GK, ed. Yellow Fever. New York: McGraw Hill. 46-136.
6. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P. 2002. Comparative safely and immunogenicity of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533-541.
7. Freestone DS, Ferris RD, Weinberg A, Kelly A. 1977. Stabilized I7D strain yellow fever vaccine: dose response studies, clinical reactions and effects on hepatic function. J Biol Stand 5: 181-186.
8. Moss-Blundell AJ, Berstein S, Shepherd WM, Langford DT, Ferris R, Kelly A. 1981. A clinical study of stabilized 17D strain live attenuated yellow fever vaccine. J Biol Stand 9: 445-452.
9. Cerna Iparraguirre FJ. 2000. EPI Directive No. 002-10-00. Lima, Peru: Ministry of Health. Division of General Person's Health (DGSP): Maternal and Child Health Program's Executive Office. Immunizations Subprogram.
10. Bryant J, Wang H, Cabezas C, Ramirez G, Watts D, Russell K, Barrett A. 2003. Enzootic transmission of yellow fever virus in Peru. Emerg Infect Dis 9: 926-933.
11. Carter K. 1998. Vectorial control of Aedes aegypti for the prevention of urban yellow fever. Carrillo C, Cabezas C, eds. Reunion de Expertos: Estrategias de Prevencion y Control de la Fiebre Amarilla y Riesgo de Urbanization en las Americas. May 14-15, 1998. Lima, Peru: U.S. Agency for International Development and Immigration and Naturalisation Service.
12. World Health Organization. 1998. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 872: 31-72. Available from URL:http://www.who.int/ biologicals/ECBS/Reports.htm.
13. Monath TP, Kinney RM, Schlesinger JJ, Brandriss MW, Bres P. 1983. Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced worldwide. J Gen Virol 64: 627-637.
14. Pugachev KV, Ocran SW, Guirakoo F, Furby D, Monath TP. 2001. Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine 20: 996-999.
15. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. 1973. Yellow fever vaccine: cured challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 539-544.
16. Spector S, Tauraso NM. 1968. Yellow fever virus. 1. Development and evaluation of a plaque neutralizing test. Appl Microbiol 16: 1770-1775.
17. World Health Organization. 1993. The Immunological Basis for Immunization. Yellow Fever. Geneva: WHO. Publication no. (WHO/EPI/GEN) 93.18, 1-13. Available from URL: http:// www.who.ch/programmes/gpv/gEnglish/avail/ gpvcatalog1.htm.
18. KS. Poland JD, Calisher CH, Monath TP, Murphy K, Downs WG. 1981. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895-900.
19. Fox JP, Cabral AS. 1943. The duration of immunity following vaccination with the 17D strain of yellow fever virus. Am J Hyg 37: 93-120.
20. Pond WL, Ehrenkranz NJ. Danauskas JX, Carter MJ. 1967. Heterotypic serologic responses after yellow fever vaccination: detection of persons with past St. Louis encephalitis or dengue. J Immunol 98: 673-682.
21. Theiler M, Anderson CR. 1975. The relative resistance of dengue-immune monkeys to yellow fever virus. Am J Trop Med Hyg 24: 115-117.
22. Monath TP. 1989. The absence of yellow fever in Asia - cause for concern? Virus Information Exchange Newsletter Southeast Asia West Pacif 6: 106-107.
23. Anonymous. 1966. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA 198: 671-672.
24. Kelso JM, Mootrey GT, Tsai TF. 1999. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 103: 698-701.
25. Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS, and The Geosentinel Yellow Fever Working Group. 2001. Advanced age as a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 7: 945-951.
26. Vasconcelos PFC, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VLRS, Monath TP, Rodrigues SG, Laval C, Costa ZG, Vilela MFG, Santos CLS, Papaiordanou CMO, Alves VAF, Andrade LD, Sato HK, Rosa EST, Froguas GB, Lacava E, Almeida LMR, Cruz ACR, Rocco IM, Santos RTM, Oliva OFP, and The Brazilian Yellow Fever Vaccine Evalualion Group. 2001. Serious adverse events associated with 17DD vaccine in Brazil: a report of two cases. Lancet 358: 91-97.
27. Kitchener S. 2004. Viscerotropic and neurotropic disease following vaccination with the yellow fever 17D vaccine ARILVAX®. Vaccine 22: 2103-2105.
28. Barwick RS, Marfin AA, Cetron MS. 2004. Yellow fever vaccine-associated disease. Scheld WM, Murray BE, Hughes JM, eds. Emerging Incetious. Sixth edition. Washington, DC: American Society for Microbiology Press. ASM Press, 25-34.